Condensation of amino groups in 5-(4-aminophenyl)-10,15,20-triphenylporphyrin and 5,10,15,20-tetrakis(4-aminophenyl)porphyrin with pentafluorobenzaldehyde resulted in corresponding Schiff bases and was shown to be a convenient route for the preparation of fluorinated porphyrin derivatives. Compounds thus obtained were easily transformed into the corresponding amines using sodium borohydride. Fluorinated carboranyl porphyrins were prepared via the nucleophilic substitution of the para-fluorine atom of pentafluorophenyl-substituted amine porphyrin derivatives with carborane S-nucleophiles. The alternative synthetic route to the fluorinated carboranyl porphyrins included the condensation of para-carboranyl-substituted tetrafluorobenzaldehyde with corresponding meso-aminoporphyrins. All prepared porphyrins were characterized by different spectroscopic techniques such as UV-vis, IR, 1H, 11B, 19F NMR and mass spectra.

No abstract

The synthesis and spectral properties of porphyrin derivative dyads are described. The dyads consist of free base 2-(2-carboxyvinyl)-5,10,15,20-tetraphenylporphyrin covalently linked to zinc 5-(p-aminophenyl)-10,15,20-triphenylporphyrin

There is a paradox when protective IgG antibodies to the SARS-CoV-2 virus are detected only in a part of patients who have contracted COVID-19. At the same time, some persons who were in contact with the infected, but did not get sick with COVID-19 (without disease symptoms, PCR negative), still produce IgG antibodies to the SARS-CoV-2 virus. The presence of IgG to the SARS-CoV-2 virus correlates with a changed immune response when infected with seasonal viral diseases - in particular, the ability to produce protective antibodies decreases. All this determines the different clinical course of the disease and the features of the patient’s post-COVID conditions (PCC). To study various immune responses of patients and asymptomatic carriers of COVID-19, 414 people were examined. The novelty of the study is that, for the first time, not only the levels of protective IgG antibody titers to the SARS-CoV-2 virus were determined, but also their correlation with the markers of lymphocyte activation CD25, CD54 (ICAM-1) and CD95 in patients who did not suffer from COVID- 19, got sick with COVID-19 and just had a heart attack. Research has scientific and practical goals, including the search for new therapeutic opportunities. Our attention was drawn to the domestic multitarget immunotherapy drug Mercurid (RP UA6098/01/01). Its ability to control T-lymphocyte activation molecules and modulate their activity was studied. The therapeutic efficiency of Mercurid was 75.6 %.